This Article Full Text Full Text (PDF) All Versions of this Article: 119/1/6    most recent CIRCULATIONAHA.108.826206v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Donahue, J. K. Search for Related Content PubMed PubMed Citation Articles by Donahue, J. K. Related Collections Animal models of human disease Arrythmias-basic studies Other Treatment Acute myocardial infarction Arrhythmias, clinical electrophysiology, drugs Gene therapy

(Circulation. 2009;119:6-8.)
© 2009 American Heart Association, Inc.

Editorial

Novel Strategy to Reduce Sudden-Death Risk in the Healing Phase After Myocardial Infarction

From the MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.

Correspondence to J. Kevin Donahue, MD, MetroHealth Medical Center, Case Western Reserve University, Rammelkamp 653, 2500 MetroHealth Dr, Cleveland, OH 44109. E-mail kdonahue@metrohealth.org

Key Words: Editorials • arrhythmia • death, sudden • gene therapy • myocardial infarction • tachyarrhythmias

An extract of the first 250 words of the full text is provided, because this article has no abstract.

For patients with reduced ejection fraction (EF), the risk of cardiac arrest is particularly high in the healing phase immediately after a myocardial infarction (MI). Estimates from recent clinical trials show an annualized sudden-death risk of 8% to 12% in the 3-month period after MI, even with optimal medical therapy including appropriate revascularization, β-adrenergic receptor blocker, aldosterone inhibitor, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy.¹

Article p 19

The recently initiated Vest Prevention of Early Sudden Death Trial/Prediction of ICD Therapies Study (VEST/PREDICTS) illustrates the gravity of this situation (clinicaltrials.gov identifier NCT00628966). VEST/PREDICTS is randomizing acute MI patients with EF 35% to wear an external defibrillator, an apparatus that consists of a jacket containing electrodes to detect the cardiac rhythm, defibrillator patches with explosive gel packs that release conductive gel immediately before a shock is delivered, and an on-board computer to interpret and manage the rhythm.² The device also contains 2 safety buttons that need to be pressed simultaneously to suppress a shock, in case the patient is still conscious when the tachycardia alarm goes off or in the event of a false alarm. Continued pressure on the buttons suppresses the shock, and release of the pressure allows the shock to proceed (assuming that the arrhythmia is still detected at that point). This suggests the unpleasant image of a patient squeezing the buttons with all available force in a panicked rush to the emergency room for less painful therapy, but, at the very least, the protection afforded by the . . . [Full Text of this Article]